Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis

Cutis

Volumn 78, Issue 5, 2006, Pages 348-354

  Jarratt, Michael T ^a   Clark, Scott D ^b   Savin, Ronald C ^c   Swinyer, Leonard J ^d   Safley, Charles F ^e   Brodell, Robert T ^f   Yu, Karen ^g  

^a DermResearch Inc   (United States)

^b Longmont Medical Research Network   (United States)

^c Savin Dermatology Center   (United States)

^d Dermatology Research Center   (United States)

^e Suncare Research Laboratories   (United States)

^f NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^g Dow Pharmaceutical Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CLOBETASOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM; FEMALE; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CLOBETASOL; DOSAGE FORMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33845655894     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-496.
2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 pt 1):401-410.
3. Lebwohl M, Sherer D, Washenik K, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002;41:269-274.
4. Rapp SR, Feldman SR, Fleischer AB Jr, et al. Health related quality of life in psoriasis: a biopsychosocial model and measures. In: Rajagopalan R, Sheretz EF, Anderson R, eds. Care Management of Skin Diseases: Life Quality and Economic Impact. New York, NY: Marcel Dekker Inc; 1998:125-145.
5. Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144(suppl 58):33-36.
6. Amin S, Cornell R, Soughton R, et al. Topical corticosteroids. In: Roenigk HH Jr, Maibach HI, eds. Psoriasis. 3rd ed. New York, NY: Marcel Dekker; 1998:453-467.
7. Al Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol. 2000;42:796-802.
8. Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70:327-332.
9. Beutner K, Chakrabarty A, Lemke S, et al. An intraindividual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol. 2006;5:357-360.
10. Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris-clinical efficacy and adrenal function. J Am Acad Dermatol. 1987;16:804-811.
11. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis. 2003;72:407-411.
12. Data on file. An open label, non-comparative evaluation of the adrenal suppression potential of clobetasol propionate 0.05% spray in subjects with moderate to severe plaque psoriasis: two and four week treatment study report D02-0204-03. Fort Worth, Tex: Galderma Laboratories, LP; 2004.
13. Temovate cream and ointment, 0.05% [package insert]. Pittsburgh, Pa: GlaxoSmithKline Consumer Healthcare LP; August 2002.